In December 2014, the company received FDA approval for the use of the 1-year inhibitor nivolumab (Opdivo) to treat patients whose skin cancer cannot be removed or has not responded to previous drug therapies. [45] In February 2015, the company initiated a research partnership with Rigel Pharmaceuticals that could generate more than $339 million. In March, the company had the exclusive opportunity to license and commercialize PROSTVAC, Bavarian Nordic`s prostate-specific Phase III antigen targeting cancer immunotherapy. Bavarian Nordic would receive an upfront payment of $60 million as well as additional payments of up to $230 million if the overall survival of the patients tested exceeds that measured in the phase II trials. Bavarian could also receive milestone payments between $110 million and $495 million, subject to regulatory approval, and these payments have a potential of up to $975 million. [46] Celgene was founded by David Stirling, Ph.D. and Sol Barer, Ph.D. as an independent biotechnology company. Bristol and Myers renamed their company Bristol, Myers Company, which grew from its home in Clinton, New York. The company moved, first to Syracuse, then, in 1899, to Brooklyn to better serve customers in New England and Pennsylvania.

In February 2015, the company acquired Flexus Biosciences for $1.25 billion. As part of this transaction, BMS will receive all rights to Flexus` IDO1 F001287 small molecule leaded inhibitor. [57] In November, the company acquired cardiovascular drug developer Cardioxyl for up to $2.075 billion. The agreement strengthens BMS`s critical pipelines with the Phase II candidate for acute decompensated heart failure, CXL-1427. [58] On October 24, 2002, Bristol-Myers formed Squibb Co. to adjust the results downwards for parts of 2000 and 2001, while that year`s profits were revised upwards due to the massive inventory that triggered two government investigations. [33] On March 15, 2004, Bristol-Myers Squibb Co. revised upwards its fourth quarter and fiscal 2003 results after reversing an earlier decision to correct accounting errors in previous years. [34] Under a deferred prosecution agreement, the company was placed under the supervision of a monitor appointed by the U.S. Attorney in New Jersey. In addition, former head of the pharmaceutical company, Richard Lane, and former chief financial officer, Fred Schiff, have been charged with federal securities violations. [35] In 2009, the company embarked on a major restructuring focused on pharmaceuticals and biologics, as well as productivity, cost reduction and streamlining initiatives through a multi-year program of continuous layoffs.

This was part of a business strategy launched in 2007 to transform the company from a large, diversified pharmaceutical company to a specialty biopharmaceutical company, which included closing half of its manufacturing facilities. [39]:19 As an additional cost-cutting measure, Bristol-Myers Squibb has also reduced health subsidies for retirees and plans to freeze its pension plan at the end of 2009. [40] [41] In 2004, Bristol-Myers agreed to pay a $150 million fine to settle the charge of accounting fraud by the U.S. Department of Justice and the Securities and Exchange Commission (SEC), although it neither admitted nor denied guilt. In 2006, the Federal Trade Commission (FTC) began investigating the company for collusion and deception by U.S. antitrust authorities over an agreement to delay the marketing of a generic version of its blood-thinning drug Plavix. Three years later, Bristol-Myers paid a $2.1 million fine to settle the charges. In February 2020, Bristol Myers Squibb and its partner Biomotiv formed a new company called Anteros Pharmaceuticals, which focuses on manufacturing drugs for inflammation and fibrosis. [73] In August, the Company announced the acquisition of Forbius and its TGF-beta 1 and TGF-beta 3 inhibitors. [74] In October, BMS announced that it would acquire cardiology company MyoKardia for $13.1 billion ($225 per share) and take control of Mavacamten, a cardiovascular drug for obstructive hypertrophic cardiomyopathy (HCM), and the development of two key treatments: Danicamtiv (MYK-491) and MYK-224.

[75] In 2019, Bristol-Myers Squibb acquired Celgene in what is considered one of the largest acquisitions of pharmaceutical companies. Celgene was founded in 1986 by David Stirling, Ph.D. and Sol Barer, Ph.D. as an independent biotechnology company. In 2002, the company was involved in a lawsuit for illegally maintaining a monopoly on Taxol, its cancer treatment, and was sued again 5 years later for the antitrust lawsuit that cost the company $125 million. [30] The deferred prosecution agreement expired in June 2007 and the Department of Justice did not pursue any further legal action against the company on matters covered by the SPL. Under the leadership of CEO Jim Cornelius, who served as CEO of Dolan until May 2010, all executives involved in the channel stuffing and generic competition scandals have since left the company. Chairman and CEO Giovanni Caforio rings the closing bell of the New York Stock Exchange to celebrate the company`s milestone. He focuses on the discovery, development and delivery of innovative medicines in a variety of therapeutic areas, including oncology and hematology, immunology and cardiovascular disease, fibrotic diseases and neuroscience. Citing major developments and a market capitalization of $87 billion and a 61.4% increase in shares, Bristol-Myers Squibb was named Best Pharmaceutical Company of 2013 by Forbes magazine.

[44] In 2009, BMS acquired biotechnology company Medarex, Inc., expanding its portfolio of oncology and immunology products. BMS focuses on treating serious illnesses in areas of significant unmet medical need. Research and development efforts focus on the following six main therapeutic areas: cardiovascular, immune sciences, metabolic, neuroscience, oncology and virology. According to BMS, its pipeline is “one of the most innovative in the industry.” But before we learn more about the drugs the company is developing, let`s take a look at its history. B@D.